IGF-1 LR3

IGF-1 LR3 Research Peptide

Long R3 IGF-1 for scientific and laboratory research. IGF-1 LR3, also written as Long R3 IGF-1 or LR3-IGF-1, is a recombinant analogue of human IGF-1 developed for laboratory research. It is not identical to endogenous human IGF-1 and should not be described as mecasermin, the recombinant human IGF-1 prescription product approved by the U.S. FDA. IGF-1 LR3 is an investigational research peptide whose published evidence is predominantly preclinical.

Understanding IGF-1 LR3

Native mature human IGF-1 is a single-chain peptide containing 70 amino acids and three intramolecular disulfide bonds. IGF-1 LR3 contains 83 amino acids. It incorporates an arginine substitution at position 3 and a 13-amino-acid extension at the amino terminus. These modifications were designed to reduce interaction with IGF-binding proteins and to increase biological activity in experimental systems compared with native IGF-1.

The term LR3 therefore describes a specific molecular analogue rather than a general form of IGF-1. Product identity should be confirmed using batch-specific analytical documentation. The product name, sequence, molecular mass, purity data and Certificate of Analysis should all refer consistently to IGF-1 LR3 rather than native IGF-1, mecasermin or another IGF analogue.

The IGF-1 signalling system

IGF-1 is an endogenous signalling peptide and growth factor produced in many tissues. Circulating IGF-1 is strongly influenced by systemic growth signalling, particularly through hepatic production, while local IGF-1 synthesis also contributes to paracrine and autocrine signalling. The IGF system includes IGF-1, IGF-2, the type 1 IGF receptor, related receptors, multiple IGF-binding proteins and binding-protein proteases. These interacting components regulate the availability, distribution and duration of IGF signalling.

Most endogenous IGF-1 in the circulation is bound to IGF-binding proteins rather than remaining freely available. IGF-binding proteins regulate transport, tissue distribution, receptor access and biological half-life. The reduced binding of IGF-1 LR3 to several IGF-binding proteins is one of the principal reasons it is used as an experimental analogue. This property can produce greater apparent potency in some cell and animal models, but the magnitude of the effect depends on the biological system, assay conditions, receptor expression and binding-protein environment.

IGF-1 primarily signals through the type 1 IGF receptor (IGF1R), a receptor tyrosine kinase within the same receptor family. Ligand binding promotes receptor autophosphorylation and recruitment of intracellular adaptor proteins. Major downstream pathways include phosphoinositide 3-kinase-AKT signalling and RAS-RAF-MEK-ERK signalling. These pathways participate in cell survival, metabolism, proliferation, differentiation and protein synthesis. Their effects are highly dependent on cell type, developmental stage and experimental context.

IGF-1 can also interact with related receptors and hybrid receptors formed with IGF1R subunits. Receptor selectivity is therefore not absolute. Experimental interpretation should consider receptor abundance, receptor isoforms and potential cross-talk between IGF and related receptor signalling. Describing IGF-1 LR3 as acting through a single isolated pathway would oversimplify the biology.

Why IGF-1 LR3 is a focus of laboratory research

Because IGF signalling can support proliferation and survival in responsive cells, IGF-1 LR3 has been used in cell-culture research involving myoblasts, fibroblasts, chondrocytes, neurons, stem-cell systems and other experimental models. It is also used in studies of receptor activation, protein synthesis, differentiation, nutrient signalling and tissue development. These are laboratory applications and do not establish activity or safety in humans.

Cellular and tissue-level biology is one prominent research area. Endogenous IGF-1 participates in myoblast proliferation and differentiation and in tissue development, and it interacts with mechanical loading, systemic growth signalling, nutrition and other signalling systems. IGF-1 LR3 has been examined in preclinical models because reduced binding-protein interaction can provide a sustained experimental stimulus. Findings from cultured cells or animal models should not be represented as proven effects in humans.

IGF signalling is also investigated in cartilage and bone biology. Endogenous IGF-1 contributes to chondrocyte function, growth-plate biology, osteoblast activity and skeletal development. Research models use IGF-1 analogues to examine receptor-dependent signalling, matrix production and cell differentiation. Outcomes can vary considerably according to species, developmental stage, local binding proteins and experimental dose.

Neurobiology represents another area of scientific interest. IGF-1 and IGF1R signalling have been studied in neuronal survival, synaptic biology, neurogenesis, glial function and responses to injury. Recent animal research has evaluated intranasal LR3-IGF-1 in neurodegenerative disease models. Such studies remain preclinical and cannot establish activity, dose relationships or safety for human neurological conditions.

Metabolic research involving IGF-1 requires particular care because the peptide has metabolic-signalling actions in some tissues. The recombinant human IGF-1 prescription product mecasermin, approved by the U.S. FDA, carries prominent labelled warnings. IGF-1 LR3 is not mecasermin, has different molecular properties and is not an approved product; the known physiology of the IGF system reinforces the need to avoid portraying IGF pathway signalling as inherently beneficial.

IGF signalling is also relevant to cancer biology. The IGF1R pathway can support proliferation and survival in some tumour models, and the pathway has been studied as a research target in oncology. This does not mean that IGF-1 causes every cancer or that all IGF signalling has the same effect, but it does mean that claims relating to tissue growth must be framed cautiously. A research product page should not promote unsupervised human use or imply that prolonged growth-factor exposure is risk-free.

Distinguishing IGF-1 LR3 from approved products

Human evidence for IGF-1 LR3 itself is extremely limited. Most human evidence in the broader IGF field concerns endogenous IGF-1 measurements, recombinant human IGF-1 such as mecasermin, or other IGF-related products. Results from those products cannot be assumed to establish the pharmacokinetics, activity or safety of IGF-1 LR3.

Mecasermin is a recombinant human IGF-1 prescription product approved by the U.S. FDA for narrowly defined paediatric indications involving severe primary IGF-1 deficiency. Its amino-acid sequence is identical to endogenous mature human IGF-1. That approval does not extend to IGF-1 LR3 or to any human, cosmetic or sporting application. livvmore should clearly distinguish its laboratory material from any approved prescription product.

IGF-1 and its analogues are also relevant to anti-doping regulation. The 2026 World Anti-Doping Agency Prohibited List includes IGF-1 and other growth factors. A research-use-only label should not be interpreted as meaning that IGF-1 LR3 is permitted in sport.

Analytical documentation and identity

At livvmore, IGF-1 LR3 should be supplied exclusively for laboratory research and analytical investigation. Every batch should have documentation confirming molecular identity, chromatographic purity, expected molecular mass, peptide content and lot traceability. For a disulfide-containing peptide, identity and structural integrity require more than a generic purity percentage.

Recommended analytical documentation may include mass spectrometry, high-performance liquid chromatography, peptide-content or assay measurement, sequence confirmation where available, and information about formulation, counter-ion, water content and storage conditions. Endotoxin and bioburden testing may be relevant for particular laboratory applications but should only be claimed when performed on the specific batch.

Researchers should recognise that potency can vary with cell line, receptor expression, binding-protein concentrations, medium composition, temperature, handling and storage. Results obtained with IGF-1 LR3 should not automatically be compared directly with native IGF-1 unless the assay design controls for these differences.

For laboratory research use only. Not for human or veterinary use.